Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System
Smith+Nephew (NYSE:SNN) has launched the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel treatment for chronic wounds. The system, which uses a patient's own platelets and plasma, is designed for managing various wound types including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
The CENTRIO PRP System is supported by two randomized controlled clinical trials and has received CMS coverage for treating chronic non-healing wounds in diabetic patients. The system can be used in both hospital and physician office settings, with the gel being customizable to fit different wound characteristics using a single blood draw.
Smith+Nephew has entered into an exclusive private label distribution agreement with Nuo Therapeutics Inc. to market the system in the United States.
Smith+Nephew (NYSE:SNN) ha lanciato il Sistema CENTRIO Platelet-Rich-Plasma (PRP), un trattamento ematogel biodinamico per le ferite croniche. Il sistema, che utilizza piastrine e plasma del paziente, è pensato per la gestione di diversi tipi di lesioni, incluse ulcere del piede diabetico, ulcere venose degli arti inferiori e piaghe da pressione.
Il Sistema CENTRIO PRP è supportato da due studi clinici randomizzati e controllati e ha ottenuto la copertura CMS per il trattamento di ferite croniche non guarenti in pazienti diabetici. Può essere impiegato sia in ospedale che negli studi medici, con il gel personalizzabile in base alle caratteristiche della ferita a partire da un unico prelievo di sangue.
Smith+Nephew ha stipulato un accordo esclusivo di distribuzione a marchio privato con Nuo Therapeutics Inc. per la commercializzazione del sistema negli Stati Uniti.
Smith+Nephew (NYSE:SNN) ha lanzado el Sistema CENTRIO Platelet-Rich-Plasma (PRP), un tratamiento hematogel biodinámico para heridas crónicas. El sistema, que utiliza las propias plaquetas y plasma del paciente, está diseñado para el manejo de distintos tipos de heridas, incluidas úlceras del pie diabético, úlceras venosas de la pierna y úlceras por presión.
El Sistema CENTRIO PRP cuenta con el respaldo de dos ensayos clínicos aleatorizados y controlados y ha recibido cobertura de CMS para el tratamiento de heridas crónicas que no cicatrizan en pacientes diabéticos. Puede utilizarse tanto en hospitales como en consultas médicas, y el gel se puede personalizar según las características de la herida a partir de una sola extracción de sangre.
Smith+Nephew ha firmado un acuerdo exclusivo de distribución con marca privada con Nuo Therapeutics Inc. para comercializar el sistema en Estados Unidos.
Smith+Nephew (NYSE:SNN)가 만성 상처 치료를 위한 생체역학적 헤마토겔 치료제인 CENTRIO Platelet-Rich-Plasma (PRP) 시스템을 출시했습니다. 환자 자신의 혈소판과 혈장을 활용하는 이 시스템은 당뇨발 궤양, 정맥성 다리 궤양, 욕창 등 다양한 상처 유형의 관리를 위해 설계되었습니다.
CENTRIO PRP 시스템은 두 건의 무작위 대조 임상시험으로 뒷받침되며, 당뇨 환자의 만성 비치유성 상처 치료에 대해 CMS 보장을 받았습니다. 병원과 의사 진료실 모두에서 사용할 수 있으며, 단일 채혈만으로 상처 특성에 맞게 젤을 맞춤 제작할 수 있습니다.
Smith+Nephew는 미국 내 시스템 마케팅을 위해 Nuo Therapeutics Inc.와 독점 사설 브랜드 유통 계약을 체결했습니다.
Smith+Nephew (NYSE:SNN) a lancé le système CENTRIO Platelet-Rich-Plasma (PRP), un traitement hématogel biodynamique pour les plaies chroniques. Le système, qui utilise les propres plaquettes et le plasma du patient, est conçu pour la prise en charge de différents types de plaies, notamment les ulcères du pied diabétique, les ulcères veineux de la jambe et les escarres.
Le système CENTRIO PRP est soutenu par deux essais cliniques randomisés et contrôlés et a obtenu une couverture CMS pour le traitement des plaies chroniques non cicatrisantes chez les patients diabétiques. Il peut être utilisé à la fois à l'hôpital et en cabinet médical, le gel pouvant être personnalisé selon les caractéristiques de la plaie à partir d'une seule prise de sang.
Smith+Nephew a conclu un accord exclusif de distribution en marque privée avec Nuo Therapeutics Inc. pour commercialiser le système aux États-Unis.
Smith+Nephew (NYSE:SNN) hat das CENTRIO Platelet-Rich-Plasma (PRP) System eingeführt, eine biodynamische Hämatogel-Behandlung für chronische Wunden. Das System nutzt die eigenen Thrombozyten und das Plasma des Patienten und ist für die Behandlung verschiedener Wundarten wie diabetischer Fußgeschwüre, venöser Beingeschwüre und Druckgeschwüre konzipiert.
Das CENTRIO PRP System wird von zwei randomisierten, kontrollierten klinischen Studien gestützt und hat eine CMS-Leistungserstattung für die Behandlung chronischer, nicht heilender Wunden bei Diabetikern erhalten. Es kann sowohl im Krankenhaus als auch in der Arztpraxis eingesetzt werden; das Gel lässt sich aus einer einzigen Blutentnahme an unterschiedliche Wundmerkmale anpassen.
Smith+Nephew hat mit Nuo Therapeutics Inc. eine exklusive Private-Label-Distributionsvereinbarung zur Vermarktung des Systems in den Vereinigten Staaten geschlossen.
- CMS coverage approval for treating diabetic patients' chronic non-healing wounds
- Backed by two randomized controlled clinical trials demonstrating efficacy
- Versatile application in both hospital and physician office settings
- Customizable gel treatment from single blood draw
- None.
Insights
Smith+Nephew's new CENTRIO PRP System enhances their wound care portfolio with clinically-proven technology that has established Medicare coverage.
Smith+Nephew has strategically expanded its Advanced Wound Bioactives portfolio with the CENTRIO Platelet-Rich-Plasma (PRP) System launch. This point-of-care biodynamic hematogel utilizes a patient's own platelets to create a customizable wound treatment solution. The system addresses a significant clinical need in chronic wound management, particularly for diabetic foot ulcers, venous leg ulcers, pressure ulcers, and tunnelling wounds.
The product's Medicare coverage through a National Coverage Determination for diabetic patients with chronic non-healing wounds significantly enhances its commercial potential. This reimbursement pathway removes a critical barrier to adoption in the US healthcare market.
What makes this launch particularly meaningful is the dual randomized controlled trials supporting CENTRIO's efficacy. This clinical evidence positions the product strongly within Smith+Nephew's existing wound care portfolio and differentiates it in the competitive wound care market.
The distribution agreement with Nuo Therapeutics allows Smith+Nephew to leverage external innovation while maintaining exclusive marketing rights. This approach enables faster portfolio expansion without the full R&D investment of internal development. For patients with difficult-to-heal wounds, this technology offers a personalized approach using their own biological materials, potentially improving outcomes for conditions that traditionally have poor healing rates and high treatment costs.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient’s own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment.
CENTRIO PRP System can help manage chronic exuding wounds including but not limited to diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers, and tunnelling wounds. Thanks to a National Coverage Determination (NCD) made effective April 2021, autologous PRP for the treatment of chronic non-healing wounds for diabetic patients has CMS coverage, when prepared by devices whose indications include the management of exuding cutaneous wounds, such as diabetic ulcers.1 The CENTRIO PRP System is designed for point-of-care use in both hospital and physician office settings and the gel can be tailored to fit wound shape, depth, and stage with a single draw of a patient’s blood. CENTRIO PRP System has demonstrated efficacy in two randomized, controlled clinical trials2,3, making it a strong fit in Smith+Nephew’s clinically proven portfolio.
Vincent Fath, SVP US Advanced Wound Management, Smith+Nephew, commented:
“CENTRIO PRP System sits perfectly alongside our portfolio of skin substitutes to offer a broad portfolio of proven biological solutions that augment healing outcomes backed by extensive clinical evidence. We are pleased to be able to expand access to this exciting and highly differentiated technology to help ease the burden of living with hard to heal wounds.”
The CENTRIO PRP System will premiere at the Smith+Nephew booth during the Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas, Nevada from September 3-6.
Smith+Nephew entered into an exclusive private label distribution agreement with Nuo Therapeutics Inc., a commercial stage medical device company pioneering biodynamic therapies, to market the CENTRIO PRP System in the United States.
To learn more about the CENTRIO Platelet-Rich-Plasma System, please visit the Smith+Nephew booth (#411) at SAWC or click here.
- ends –
Media Enquiries
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
References
- NCD - Blood-Derived Products for Chronic Non-Healing Wounds (270.3)
- Gude, Warren MD; Hagan, Daniel DPM, DABPS; Abood, Ferial MD; Clausen, Peter PhD. Aurix Gel Is an Effective Intervention for Chronic Diabetic Foot Ulcers: A Pragmatic Randomized Controlled Trial. Advances in Skin & Wound Care 32(9):p 416-426, September 2019. | DOI: 10.1097/01.ASW.0000577140.19174.9e
- Driver VR, Hanft J, Fylling CP, Beriou JM; Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006 Jun;52(6):68-70, 72, 74 passim. PMID: 16799184.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
FAQ
What is Smith+Nephew's CENTRIO PRP System and how does it work?
Does Medicare cover Smith+Nephew's CENTRIO PRP System?
What types of wounds can be treated with SNN's CENTRIO PRP System?
What clinical evidence supports Smith+Nephew's CENTRIO PRP System?
Where will Smith+Nephew's CENTRIO PRP System be available?
